What is the brand name for the combination medication containing salmeterol and fluticasone?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Brand Names for Salmeterol/Fluticasone Combination

The brand name for the combination medication containing salmeterol and fluticasone is Advair Diskus (or Wixela Inhub for the generic version).

Salmeterol/Fluticasone Combination Details

Salmeterol/fluticasone is a fixed-dose combination medication that contains:

  • Salmeterol: A long-acting beta2-agonist (LABA) bronchodilator
  • Fluticasone propionate: An inhaled corticosteroid (ICS)

This combination is available in several formulations:

  • Advair Diskus (original brand name) - dry powder inhaler
  • Wixela Inhub (generic version) - dry powder inhaler
  • Advair HFA (metered-dose inhaler version)
  • Seretide (brand name used in some countries outside the US)

Available Strengths

The combination is available in three strengths, with the same amount of salmeterol but varying amounts of fluticasone 1:

  • 100/50 mcg (100 mcg fluticasone propionate/50 mcg salmeterol)
  • 250/50 mcg (250 mcg fluticasone propionate/50 mcg salmeterol)
  • 500/50 mcg (500 mcg fluticasone propionate/50 mcg salmeterol)

Clinical Applications

This combination medication is primarily used for:

  • Maintenance treatment of asthma in patients not adequately controlled on other medications 2
  • Maintenance treatment of airflow obstruction in patients with COPD 3

Pharmacological Properties

The combination offers complementary effects:

  • Salmeterol: Provides bronchodilation through beta2-receptor stimulation
  • Fluticasone: Provides anti-inflammatory effects through glucocorticoid receptor binding

Studies have confirmed that Wixela Inhub is bioequivalent to Advair Diskus at all three dose strengths for both fluticasone propionate and salmeterol, providing equivalent systemic safety and pulmonary deposition 4.

Important Clinical Considerations

  • Multiple ICS/LABA combinations should never be used simultaneously due to therapeutic duplication and increased risk without additional benefit 5
  • The combination has shown benefits in reducing exacerbations in patients with COPD compared to monotherapy 3
  • In patients with asthma, the combination improves lung function and symptoms more effectively than monotherapy with either component 2, 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.